PRECISION RESEARCH MODELS INSIGHTS


What's in a Name? Origins of the CIEA NOG mouse®

The CIEA NOG mouse® is often referred to as an ideal mouse for engraftment of foreign (especially human) cells. The high rates of engraftment make NOG mice a preferred choice for patient-derived xenografts and humanized immune system mice studies. What special properties make the NOG mouse such a great acceptor of foreign cells and tissues? To answer this question, one need only look at the mouse line's...

Read More

Copy Number Variation, Microdeletion, and Disease

Copy number variations (CNVs) are duplications and deletions to large (~5kb-5mb) genomic regions found in varying degrees within the human population. These duplications and deletions significantly contribute to human genetic diversity and can dramatically affect gene-dosage. Recently, pathologic and highly-penetrant CNVs have been identified in patients with neurodevelopmental and psychiatric disorders. The microdeletion at chromosome location 15q13.3 is one example. This CNV can result in a range...

Read More

Guidelines for Use of Humanized Mice in IBD Drug Discovery

Inflammatory Bowel Disease (IBD) is a chronic immunologically mediated disease with no known cure. Can humanized mice speed up IBD drug discovery, bringing relief to the estimated 1.4 million Americans with this difficult condition? To support IBD research, Taconic hosted a webinar by TransCure BioServices experts: Chief Executive Officer (CEO), Dr. Patrick Nef, and Chief Scientific Officer (CSO), Dr. Sebastien Tabruyn. TransCure is a contract research organization...

Read More

Are Humanized Mice the Future of Oncology Models?

Oncologists are up against the limits of cell cultures and xenografts in applied research. Are humanized mice the solution? In an article discussing the challenge of tumor heterogeneity, Drug Discovery News (DDN) laid out several factors which contribute to heterogeneity and which complicate the clinical presentation of tumors, but which are not well modeled in cell culture: Genetically diverse subclonal populations, both within a tumor and across...

Read More

Preclinical Immuno-Oncology Animal Models

Immuno-oncology - triggering a patient's own immune system to attack their cancer - is sweeping through all levels of oncology research, from academia to biotech and pharma. Silicon Valley mogul Sean Parker, co-founder of Napster and first president of Facebook, pledged $250 million to set up the Parker Institute for Cancer Immunotherapy. Pharma and biotech are betting big on immunotherapy also, with significant resources devoted to immunotherapy...

Read More

Patient-derived Xenografts of Hematological Malignancies Webinar Review

Dr. Julia Schueler of Oncotest presented a webinar exploring her work with patient-derived xenografts (PDX) of hematological malignancies as model systems for drug development and tumor biology research. PDX models of hematological origin provide the same advantages as solid tumor PDX models, such as preserving tumor heterogeneity and the treatment sensitivity profile of the donor patient. View the webinar: Patient-Derived Xenografts of Hematological Malignancies For successful development...

Read More

Review: Humanized Mouse Model Research Symposia

Humanized mouse models are critical tools for basic research, modeling of certain human-specific infectious diseases, efficacy testing of immunotherapy approaches, and safety assessment for large molecule therapeutics. Taconic Biosciences recently hosted the symposium series "Advanced Preclinical Models for Immuno-oncology and Infectious Disease" in several European cities, which focused on the latest research applications of human immune system engrafted mice and the introduction of next generation models. International...

Read More

Patient-Derived Xenografts Q&A with Dr. Els Hermans

Dr. Els Hermans, whose work on the Trace platform at KU Leuven is streamlining the oncology R&D pipeline, presented a webinar focused on the application of patient-derived xenograft models (PDX) in translational cancer research. Her presentation on use of PDX models to close the gap between pre-clinical and clinical trials, and their application in personalized medicine, generated substantial interest from the research community. View the webinar: Patient-Derived...

Read More

Patient-derived tumor xenograft (PDX) models - An emerging way to personalized medicine in translational cancer research

Dr. Els Hermans of the Trace platform at KU Leuven presented a webinar focused on patient-derived xenografts (PDX). Dr. Hermans framed the discussion by introducing existing problems in cancer drug discovery and development. A lack of predictive and reliable preclinical animal models has contributed to failure of new therapies in the clinic. PDX models may be a better tool for oncology research as they recapitulate intra-tumor heterogeneity...

Read More

Comparison Guide: huNOG-EXL, NSG-SGM3 and MISTRG

Several super immunodeficient models expressing cytokines designed to drive myeloid cell lineage commitment have been generated. The most advanced cytokine transgenic mouse models are the huNOG-EXL, NSG-SGM3 and the MISTRG. This group of models has promise to improve human immune system engraftment in mice, but each one has different features which must be considered when choosing an experimental model. Each model expresses two or more human variants...

Read More